Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia

ConditionAcute Myeloid Leukemia

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorCiceri Fabio

About this trial

The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.

Eligibility criteria

Qualifiers

Any gender,

Adults (>18 years old),

New suspect diagnosis of acute myeloid leukemia (ELN2022 Criteria)

Capable of comprehend the study and the consent form,

Disqualifiers

Pediatric patients (<18 years old),

Patients unable or unwilling to sign the informed consent.

Trial design

Treatments tested in this trial

Clinical Practice

Treatment groups

80 Participants

are divided into 1 treatment group

Sponsors and collaborators

Ciceri Fabio

Lead sponsor

IRCCS San Raffaele

Sponsor institution

Azienda Ospedaliera Bianchi-Melacrino-Morelli

Collaborator

Source ClinicalTrials.gov